HuYu-B (02256) announced that its subsidiary, shanghai HuYu Biomedical Technology Co., Ltd., presented preliminary Phase II study results of pembrolizumab (ABSK021) in patients with chronic graft-versus-host disease ("cGvHD") who have failed previous first-line or multiline therapy at the 66th American Society of Hematology ("ASH") Annual Meeting, held in San Diego, California, USA, from December 7 to 10, 2024, in the form of an oral presentation. Although most enrolled patients have not completed the required 6-month treatment cycle for cGvHD response assessment, preliminary data from the subset of patients treated with pembrolizumab 20 mg QD show an ORR of 64%.
As of November 22, 2024, a preliminary observation of 64% ORR was seen in the subset of patients treated with pembrolizumab 20 mg QD, with resolution observed in all affected organs, including the gastrointestinal tract, oral cavity, eyes, liver, joints and fascia, esophagus, skin, and lungs.
